Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$381 Mln
Revenue (TTM)
$247 Mln
Net Profit (TTM)
$0 Mln
ROE
-21 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
12.3
Industry P/E
24.51
EV/EBITDA
-2.3
Div. Yield
0 %
Debt to Equity
-2.6
Book Value
$--
EPS
$-1.9
Face value
--
Shares outstanding
104,390,000
CFO
$-1,286.48 Mln
EBITDA
$-1,591.51 Mln
Net Profit
$-1,894.36 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Revance The (RVNC)
| 20.1 | 18.1 | -37.5 | -28.4 | -35.1 | -32.0 | -14.0 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Revance The (RVNC)
| -65.1 | -52.4 | 13.1 | -42.4 | 74.6 | -19.4 | -43.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug... candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. As of February 6, 2025, Revance Therapeutics, Inc. operates as a subsidiary of Crown Laboratories, Inc. Read more
CEO & Director
Mr. Mark J. Foley
CEO & Director
Mr. Mark J. Foley
Headquarters
Nashville, TN
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Revance The (RVNC) is $3.65 (NASDAQ) as of 06-Feb-2025 16:00 EDT. Revance The (RVNC) has given a return of -35.11% in the last 3 years.
Since, TTM earnings of Revance The (RVNC) is negative, P/E ratio is not available.
The P/B ratio of Revance The (RVNC) is 12.30 times as on 06-Feb-2025, a 117 premium to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-2.45
|
-5.23
|
|
2022
|
-4.15
|
117.39
|
|
2021
|
-3.87
|
16.22
|
|
2020
|
-6.36
|
4.79
|
|
2019
|
-4.74
|
3.28
|
The 52-week high and low of Revance The (RVNC) are Rs -- and Rs -- as of 05-Apr-2026.
Revance The (RVNC) has a market capitalisation of $ 381 Mln as on 06-Feb-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Revance The (RVNC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.